The Latest Evidence on Informed Consent in Clinical Trials
A recent systematic review reveals incredible detail about informed consent in clinical trials, participant understanding, and trial quality. Find out now.
Articles, expert interviews, and insights from life sciences leaders
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Anthropic’s Gates Foundation Partnership and Healthcare AI
See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.
Optimising Clinical Trial Data Collection for Better Decisions
Learn how optimised clinical trial data collection improves data quality, reduces protocol and patient burden, and supports smarter clinical development.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
Claude Science: An Operating System for AI-Driven Pharma R&D
Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.
Deep Learning in Clinical Trials for 2026 and Beyond
Deep learning is changing how clinical trials are designed, run, and analysed in 2026. Examine the tools, outcomes, and strategic risks shaping adoption.
Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
AI and Neuroscience. Why Big Pharma Is Betting on the Brain
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
11 Clinical Trials Defining Pharmaceutical Strategy in 2026
We've mapped the competitive, regulatory, and commercial stakes of the top 11 clinical trials that have defined pharma strategy so far in 2026.
Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
How AI Is Reshaping Data Integrity in Pharma Manufacturing
Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.
